Veeva Systems (NYSE: VEEV) beat on revenue and earnings for Q2, then lifted its full-year guidance across every metric. The beat itself was solid, not shocking. What makes this quarter worth attention is the narrative underneath: Veeva is accelerating its AI push while its core CRM business is winning at a pace that suggests the competitive landscape is shifting in its favor.
Revenue hit $928.0M, up 18% year over year and roughly $22.6M above the consensus estimate of $905.4M. Subscription revenue rose 16% to $766.8M; professional services grew 24% to $161.2M. Non-GAAP diluted EPS of $2.35 beat the $2.22 estimate and rose 18% from $1.99 a year ago. Non-GAAP operating margin held steady at 44.8%, essentially flat with the prior year's 44.7%.
The headline numbers are clean. The operating margin stability is the detail that matters. Veeva is growing at 18% while keeping non-GAAP margins nearly unchanged. That is not easy to do when you are also investing in new product areas. The company spent $222.9M on R&D in the quarter, up 16% year over year, and that line includes the costs of building out the Falcon AI platform and integrating the recently acquired Copli. The margin hold suggests the incremental revenue from the core business is funding the AI buildout without diluting profitability.
Full-year guidance was raised across the board. Revenue is now expected between $3,682M and $3,687M, up from the prior range. Non-GAAP operating income is guided to approximately $1,640M, and non-GAAP EPS to roughly $9.21. The Q3 guide calls for revenue of $932M to $935M and non-GAAP EPS of $2.33 to $2.34. The full-year raise is modest in percentage terms. Revenue guidance went up by roughly $10M at the midpoint, and EPS by about $0.01. That is not a dramatic revision. But the fact that management felt confident enough to raise at all, given the macro uncertainty in life sciences spending, is a positive signal.
The real story of the quarter is Vault CRM. The press release calls it the best quarter ever for that product. Twelve of the top 20 biopharma companies globally are now committed to Vault CRM, and a top-20 pharma deployed both Vault CRM and the Agentic Call Report across its entire U.S. field team in the quarter. That is a reference-able win. When a top-20 customer goes all-in on a new CRM platform, it creates a proof point that the rest of the industry notices. Veeva now has more than 180 Vault CRM customers live, including five top-20 biopharmas. The migration from the legacy CRM platform is happening, and it is accelerating.
On the AI front, Veeva Falcon has five early adopters and is on track for initial go-lives this year. The company also launched Falcon MLR for automated content reviews and acquired Copli during the quarter. The AI narrative is still early. Five early adopters is not a revenue driver yet. But the pace of product launches and the acquisition suggest Veeva is not waiting for the market to come to it. It is building the platform now.
The R&D and Quality side of the business also showed momentum. Veeva Safety surpassed 100 total customers and secured its second top-20 biopharma win for Safety Workbench. Quality added more than 30 new customers in the quarter. These are smaller numbers than the CRM wins, but they show the cross-sell engine is working. A customer that starts with Veeva for commercial often expands into R&D and quality over time.
The balance sheet remains fortress-grade. Cash and short-term investments total $7.24B, and the company generated $1.37B in operating cash flow in the first half of the fiscal year. Veeva also repurchased $472.7M of its own stock during the six-month period. That is a meaningful capital return for a company that historically did not buy back shares. The buyback pace is aggressive relative to the company's history, and it signals that management sees the stock as undervalued at current levels.
What to watch next: the pace of Vault CRM migrations and the Falcon go-lives. The CRM wins are the near-term revenue driver, and the conversion of those commitments into live deployments will determine whether the subscription revenue growth rate can accelerate from the current 16%. The Falcon AI platform is the longer-term bet. If initial go-lives this year lead to broader adoption in fiscal 2028, the AI narrative will have real revenue behind it. For now, Veeva is executing well, investing aggressively, and returning capital to shareholders. That is a combination that works.